Objectives. I.v. iloprost (ILO) may be used in the treatment of refractory RP and digital ulcers. We aim to evaluate the acute and chronic effects of two different ILO regimens by power Doppler US (PDUS) and nailfold videocapillaroscopy.
Introduction
SSc is a multi-organ disease characterized by immune dysregulation, tissue fibrosis and vascular impairment [1] . Intimal hyperplasia, endothelial cell dysfunction and occlusive vasculopathy are prominent features of the vascular involvement [2] . In particular, vascular disease-specific manifestations are quite frequent in SSc patients; RP is the most common manifestation, affecting $96%, and about 75% of patients experience digital ulcers (DUs) during the first 5 years of the disease [3] .
According to recently revised EULAR recommendations for SSc treatment, dihydropyridine-type calcium antagonists (usually nifedipine) are suggested as first-line therapy for RP, and Phosphodiesterase type 5 (PDE-5) inhibitors can also be considered. I.v. prostanoids, in particularly iloprost (ILO), should be used, after oral therapy failure, for severe RP [4] . Furthermore, i.v. ILO is considered effective for DU healing and it should be considered in the treatment of DU [4] . Unfortunately, recommendations do not provide any indications about i.v. ILO dosage and regimen.
Although there is some evidence from clinical trials [57] , nowadays, in clinical practice, i.v. ILO is administered according to different non-validated regimens, often based on the physician's experience.
Several imaging modalities are available to monitor therapeutic effects. According to our knowledge, there are no recommendations for the use of a specific validated imaging technique [811] . Previous studies described the utility of some echographic [1113] and capillaroscopic [14, 16] parameters in order to assess vascular involvement in patients with SSc.
In our clinical practice SSc patients are treated with i.v. ILO for RP refractory to oral therapy or for DU. Two different regimens (1 day monthly and five consecutive days every 3 months) may be administered to patients according to their own preferences and needs.
The aim of our study was to evaluate the acute and chronic effects of two different ILO regimens as assessed by imaging techniques such as power Doppler US (PDUS) and nailfold videocapillaroscopy (NVC).
Methods

Study design
This was a 3-month observational, prospective, pragmatic, single-centre and no-profit study. The study complies with the Declaration of Helsinki. The local ethical committee (Comitato Etico Milano Area B) granted ethical approval (591_2016bis), and written consent forms were obtained from all subjects. We designed the study as a pragmatic trial because our intention was to estimate the impact of two different i.v. ILO regimen in SSc patients [1719] .
The study population consisted of all consecutive individuals aged 518 years who met the 2013 ACR criteria for SSc [20] referring to our in-and out-patient rheumatology clinic (Azienda socio-sanitaria territoriale Pini-CTO, Università degli Studi di Milano, Milan, Italy). Patients were enrolled between autumn 2016 and winter 2017.
Patients were excluded if they had an overlap syndrome, had the amputation of the third or fourth finger of the dominant hand, or declined to sign the informed consent or were not able to understand the study protocol.
Each patient was treated according to current clinical practice and stratified into three main groups: SSc patients from the out-patient clinic not requiring therapy with i.v. ILO (group A), SSc patients treated with i.v. ILO once monthly (group B) and SSc patients treated with i.v. ILO for five consecutive days every 3 months (group C). Groups B and C were treated with i.v. ILO at the dosage of 0.52.0 ng/kg/min for six consecutive hours.
Group A was then evaluated after 3 months. Group B was evaluated every month, before and after 6 h infusion, for three consecutive months (a total of four ILO infusions were administered). Group C was evaluated at baseline before and after 6 h and 5 days of therapy, and again after 3 months (supplementary Fig. S1 , available at Rheumatology online).
Acute and chronic ILO effects were evaluated for each treatment group. For the acute ILO effect a comparison between pre-treatment and 6 h post-treatment measurements was performed; in addition, for patients treated for five consecutive days every 3 months a comparison between 6 h post-treatment and 5 days post-treatment was performed. For the chronic ILO effect the comparison between measurements before therapy at baseline and measurements before therapy at 3 months of follow-up was considered.
Physical examinations, demographic data, SSc-related parameters, comorbidities and pharmacological therapy were recorded at baseline, at each visit before the infusion and after 3 months (supplementary Table S1 , available at Rheumatology online).
Safety was assessed by adverse events, serious adverse events, discontinuations due to adverse events and laboratory observations.
Outcomes
The primary endpoint was to evaluate acute and chronic effects of ILO administered with two different regimens (groups B and C) as assessed by PDUS. Secondary endpoints included the assessment of acute and chronic ILO effects by NVC.
PDUS
All the exams were performed after 15 min of acclimation in a room with an ambient temperature ranging from 19 to 22 C by the same operator (T.S.). US measurements were performed using the same US apparel (MyLab 70 XVG by Esaote (Genova, Italy) equipped with a highfrequency, 1022 MHz, linear-array probe). Greyscale frequency was set to 22 MHz; power Doppler settings were standardized for all evaluations (frequency 14.3 MHz, gain 55%, pulse repetition frequency 750 Hz). No pressure was applied on fingers to prevent mistakes due to leaving a layer of gel between the probe and patient's skin.
US was performed at the third and fourth finger of the dominant hand if ulnar artery occlusion (UAO) was not found. UAO was defined as an abolition of blood flow as assessed by US. UAO was confirmed by Allen test and, if found positive, the non-dominant hand was evaluated. If UAO was found at both hands, the dominant hand was considered.
Resistivity index (RI) was calculated at radial and ulnar proper digital arteries at the level of the proximal phalanx of the third and fourth fingers. Each estimation has been performed twice for every anatomical site. The transducer was held transversal to the long axis of the artery examined. The RI was calculated using on-board software.
Peripheral vascularization was evaluated at finger pulp and nailbed area for the same fingers considered for RI.
As shown in Fig. 1 , finger pulp blood flow (FPBF) and periungual vascularization were graduated according to Newman et al. [21] from 1 (no signal) to 4 (yellow). The transducer was held sagittal to the nailbed for periungual vascularization and FPBF. NVC NVC was performed using equipment with a 200Â optical probe, with the images being captured, coded and stored using Videocap software (DS-Medica, Milan, Italy). All of the recordings were made with the subject in a sitting position, with temperature ranging from 22 to 25 C and with their hands at heart level. The procedure was explained and a drop of immersion oil was applied to the nailfold to maximize the translucency of the keratin layer.
The exams were performed by two operators (T.S. and F.I.), and capillaroscopic images were evaluated by an experienced observer (F.I.).
At baseline and after 3 months, all the fingers, excluded thumbs, were examined in order to establish the overall pattern classified as within the normal range [22] or scleroderma pattern [23] . Moreover, at the third and fourth finger of the same hand analysed by US, the sum of capillaries width apex in 1 mm was calculated [24] .
Statistical analysis
Distribution of PDUS and NVC measurements regarding the three groups (AC) at the corresponding detection times are reported in terms of percentages for categorical variables (FPBF and periungual vascularization) and in FIG. 1 PDUS grading system used at nailbed and finger pulp PDUS: power Doppler US.
terms of mean for continuous variables (RI and sum of capillaries width apex).
As regards the acute or chronic effect of ILO on periungual vascularization (or FPBF), ordinal logistic models were fitted. The response variable was periungual vascularization or FPBF (using four ordinal categories). To evaluate the acute effect, the explanatory variables were time (pre-and post-therapy), follow-up time (baseline, 1, 2 or 3 months, as adjusting variable) and temperature (as adjusting variable); the interaction between time and follow-up time was also considered to evaluate whether the effect of the therapy was different depending on follow-up time. To evaluate the chronic effect, the explanatory variables were follow-up time (at baseline and at 3 months of follow-up) and temperature (as adjusting variable). In order to take into account the association between measures of periungual vascularization or FPBF on the same finger and on the same patient, finger and subject ID are included in the model as random effects. For each grade category j, the exponential of the regression coefficient of this regression model is interpreted as the ratio of the odds of being above category j after the therapy and the odds of being above category j before the therapy. This model assumes that the odds ratio is the same for each category j. An odds ratio >1 indicates that after the therapy, there is a greater percentage of patients with higher grade of periungual vascularization or FPBF.
As regards an effect of ILO on RI (or sum of capillary width), linear regression models were fitted. The response variable was the RI (or sum of capillary width). To evaluate the acute effect, the explanatory variables were time (preand post-therapy), follow-up time (baseline, 1, 2 or 3 months, as adjusting variable) and temperature (as adjusting variable); the interaction between time and followup time was also considered to evaluate whether the effect of the therapy was different depending on followup time. To evaluate the chronic effect, the explanatory variables were follow-up time (at baseline and at 3 months of follow-up) and temperature (as adjusting variable). In order to take into account the association between measures of RI (or sum of capillary width) on the same finger and on the same patient, finger and subject ID are included in the model as random effects. The regression coefficient of this model is interpreted as the mean difference of RI (or sum of capillary width) before and after ILO treatment.
To assess whether the variation in PDUS or NVC measurements is different according to average temperature in the patient's place of residence during the week before the evaluation, an interaction term between time and temperature was considered.
All analyses were performed using R software, version 3.4.3, with packages lmerTest and ordinal added.
Results
Study population
Between autumn 2016 and winter 2017, a total of 109 SSc patients were enrolled in the study. Thirteen did not satisfy eligibility criteria and were excluded. Among the 96 SSc patients included, 52 were not on ILO therapy (group A), 24 were treated with i.v. ILO 1 monthly (group B) and 20 received i.v. ILO 5 days every 3 months (group C). Of these, for each group, respectively, 35, 21 and 16 completed the study. The proportion of patients who discontinued treatment was similar between the two treatment arms (Fig. 2) . Since this was a pragmatic trial, patients were stratified according to former therapy. Therapeutic regimen was not modified with trial enrolment.
Baseline demographics, disease characteristics, internal organs involvement, physical examination and autoantibody profile were similar between groups of patients included in the final analysis ( Table 1 ). The three groups were similar in terms of vascular involvement (i.e. visual analogue scale severity for RP, presence of DUs, gangrene and pitting scars). Detailed information on treatment and comorbidities is available in supplementary Tables S2S6, available at Rheumatology online.
Acute effect of ILO infusion
The results of the ordinal logistic regression and the linear regression models are reported in Table 2 . In group B, a significant increase was observed in periungual vascularization (P < 0.001), FPBF (P < 0.001) and RI (P < 0.001). The acute effect of ILO was observed at every infusion from baseline throughout the whole follow-up period (Fig. 3) .
Similarly in group C, FPBF increased significantly 6 h after the therapy (P = 0.005) and a further increase was observed thereafter (P = 0.017). The same trend was observed for periungual vascularization, even though its increase was not statistically significant. RI increased significantly only after 5 days of therapy with respect to the end of the first day of therapy (P = 0.002).
In both groups the sum of capillaries width apex was not different before and after infusion, although it is possible to observe a progressive trend (group B: P = 0.257 and group C: P = 0.364 after the first day of therapy and 0.192 after the fifth day of therapy).
Distribution of PDUS parameters (FPBF, periungual vascularization and RI) and NVC (sum of capillaries width apex) measurements regarding the three groups before and after 6-h infusion are reported in supplementary Table S7 , available at Rheumatology online.
Chronic effect of ILO infusion
No differences in imaging parameters (i.e. PDUS and NVC) were observed between baseline and before the last round of therapy in both groups of patients, suggesting that i.v. ILO effects cannot be maintained overtime (supplementary Table S8 , available at Rheumatology online).
Since allocation to groups was not performed randomly, a direct comparison between them cannot be conducted. However, two considerations can be drawn: at baseline patients not requiring i.v. ILO therapy tended to have a better grade of vascularization (FPBF and Fig. 4 .
Temperature effect
Finally, we studied whether outdoor temperature was able to affect treatment response assessed by PDUS. In particular, in group A the difference in RI between baseline and after 3 months tended towards increasing concurrently with the reduction of temperature; moreover, taking into account the acute effect of ILO, FPBF increased in group B and RI increased in group C concurrently with the decrease of outdoor temperature. By contrast, outdoor temperature did not have an impact on chronic effect in the two treatment groups.
Discussion
I.v. ILO is currently used to treat RP and DU secondary to SSc, even though no precise indications about the regimen have been suggested. Moreover, according to some authors, i.v. ILO, based on its biological properties, might play a role as a DMARD [25] .
In our clinical practice we propose i.v. ILO to SSc patients with RP not adequately controlled by oral therapy (i.e. calcium channel blockers) or with DU. Patients can choose between two different regimens (once monthly or 5 consecutive days every 3 months) according to their own preferences and needs.
I.v. ILO therapy was able to cause an acute effect with respect to the PDUS parameters considered. The acute effect was statistically significant in group B, while in group C statistical significance was not reached for all the parameters. On the contrary, the i.v. ILO effect observed immediately after the infusion was no longer detectable before the following infusion. This means that the acute effect, as assessed by PDUS, is not maintained over time until the next infusion. These data support the need for further studies to understand the optimal timing of the retreatment strategy.
Since this study was a non-interventional pragmatic study, a direct comparison between treatment groups was not feasible. Despite this consideration, patients receiving i.v. ILO showed at baseline worse levels of peripheral vascularization (PDUS and periungual vascularization) compared with patients not requiring i.v. ILO.
FIG. 4 Changes of PDUS parameters over time
Finger pulp blood flow (A) and periungual vascularization (B) at T0: baseline; T1: 1 month follow-up; T2: 2 months followup; T3: 3 months follow-up. PDUS: Power Doppler US.
The opportunity for discontinuing i.v. ILO therapy during summer is a subject of ongoing debate. In our study the outdoor temperature was able to inversely influence the acute response to ILO therapy for some of the PDUS parameters considered. These results might support a rationale for i.v. ILO summertime suspension even though we performed the study during the autumnwinter period, and some studies have suggested the opposite [26] .
Future studies are needed to assess how long i.v. ILO effects last and to assess the best i.v. ILO regimens. Moreover, it is of fundamental importance to validate the imaging parameters to monitor the therapeutic effects.
